Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Tri Pointe Homes, Inc. to Sumitomo Forestry Co., Ltd. to assess the adequacy of the sale price and process involved in the transaction [1] Group 1: Proposed Sale Details - Under the proposed transaction, shareholders of Tri Pointe Homes will receive $47.00 in cash for each share they own [1] - The investigation aims to determine if this consideration undervalues the company and whether the process leading to this valuation was adequate [1] Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can contact Kahn Swick & Foti, LLC to discuss their legal rights without any obligation or cost [1] - Contact details for Kahn Swick & Foti, LLC include a toll-free number (855-768-1857) and an email address for inquiries [1]

Core Viewpoint - Varonis Systems, Inc. is facing a class action lawsuit due to allegations of misleading investors about its revenue outlook and growth potential, leading to significant stock price decline after disappointing financial results [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Molchanov v. Varonis Systems, Inc., and it involves investors who purchased Varonis common stock between February 4, 2025, and October 28, 2025 [1]. - The lawsuit claims that Varonis and its executives violated the Securities Exchange Act of 1934 by providing false information regarding the company's revenue projections and growth while downplaying risks associated with seasonality and macroeconomic factors [1]. - On October 28, 2025, Varonis reported third-quarter results that significantly missed prior projections, leading to a nearly 49% drop in stock price [1]. Group 2: Allegations Against Varonis - The complaint alleges that Varonis misrepresented its ability to maintain annual recurring revenue growth and the effectiveness of its sales team in converting existing clients to its SaaS offerings [1]. - CEO Yakov Faitelson attributed the revenue shortfall to lower renewals in both Federal and non-Federal subscription businesses during the final weeks of the quarter [1]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Varonis common stock during the class period to seek appointment as lead plaintiff in the lawsuit [1]. - The lead plaintiff represents the interests of all class members and can choose a law firm to litigate the case [1]. - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [1]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in complex class action litigation, having recovered over $916 million for investors in 2025 alone [1]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [1].

Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for allegedly materially misstating its financial statements and lacking adequate internal controls, leading to a significant drop in stock price [1] Group 1: Allegations - The lawsuit claims that Kyndryl's financial statements during the class period were materially misstated [1] - It is alleged that Kyndryl lacked adequate internal controls and materially understated issues related to these controls [1] - The company failed to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, in a timely manner [1] Group 2: Impact on Stock Price - Following the announcement of the late filing and the SEC investigation, Kyndryl's stock price fell by $12.90 per share, or 55%, closing at $10.59 on February 9, 2026 [1] Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers to the court by April 13, 2026 [1] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [1]

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Paysafe Limited (NYSE: PSFE) securities between March 4, 2025 and November 12, 2025. Paysafe provides end-to-end payment solutions in the United States and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations tha ...

LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Black ...

NEW YORK, Feb 13 (Reuters) - JPMorgan Chase (JPM.N), opens new tab must face part of a proposed class action lawsuit accusing the largest U.S. bank of paying brokerage and retirement account holders near-zero interest rates instead of market rates on their idle cash, a federal judge ruled. Customers alleged that the Cash Sweep programs in which they were automatically enrolled "siphoned billions of dollars in net interest income," by paying artificially low 0.01% to 0.03% interest even as the federal funds ...

PHILADELPHIA, Feb. 13, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) (“uniQure” or the “Company”) on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025 (the “Class Period”). Investor Deadline: Investors who purchased uniQure securities during the Class Period may, no later than April 13, 2026, seek to b ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Paysafe Limited of Class Action Lawsuit and Upcoming Deadlines - PSFE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Paysafe Limited ("Paysafe" or the "Company") (NYSE: PSFE). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Thos ...

AGL LAWSUIT ALERT: The Gross Law Firm Notifies agilon health, inc. Investors of a Class Action Lawsuit and Upcoming Deadline [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of agilon health, inc. (NYSE: AGL).Shareholders who purchased shares of AGL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to parta ...